HIV Prevention

;

Comments to Washington Prescription Drug Affordability Board on HIV treatment and cost of care

Sep 16, 2024

While patients currently have access to free or affordable HIV medications through various avenues, we are concerned that setting an arbitrarily low price for these treatments could negatively impact future drug development and reduce manufacturers’ willingness to continue providing medications to millions of people in underdeveloped and underserved nations. It is essential that manufacturers have the necessary incentives to invest in research and development, enabling the creation of longer-acting treatments, preventive drugs, vaccines, and potentially even a cure for the virus. Overlooking the impact of current assistance programs on HIV treatment affordability, as well as mandating alternative drug options, disregards the nuances of HIV care and the unique requirements of each patient.

read more

Oppose domestic HIV programs cuts of over $541 million in Labor HHS approps. bill

Jul 9, 2024

There are currently over 1.2 million people living with HIV in the United States and approximately 32,000 new diagnoses annually, with only 65 percent of people virally suppressed and only 36 percent of the people who would benefit from PrEP on it. While we are making progress, racial, ethnic, gender, and geographic disparities persist, and continued investments are needed to reduce new infections and bring more people into care and treatment.

read more

Senate testimony on FY25 appropriations for HIV and hepatitis programs

May 24, 2024

Our nation can eliminate both HIV and viral hepatitis, but without investing additional resources to accelerate our efforts, we will continue to fall short of these ambitious goals. Increased investment–and certainly not cuts–in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis, which include taking a syndemic approach to achieve maximum impact.

read more

Comments to MD Prescription Drug Affordability Board on HIV treatments

May 15, 2024

While we are supportive of the Maryland Prescription Drug Affordability Board (PDAB) goal of improving treatment affordability, we urge PDAB members and staff to address concerns surrounding access to provider-recommended HIV treatments at the individual level and the impact on broader public health goals and provide clarity around the affordability review process to enable meaningful community input.

read more

House testimony on FY25 appropriations for HIV and hepatitis programs

May 3, 2024

Our nation can eliminate both HIV and viral hepatitis, but without an infusion of new resources to accelerate our efforts, we will continue to fall short of these ambitious goals. While we realize strict spending caps are in place, increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis, which include taking a syndemic approach to achieve maximum impact. The programs and funding increases detailed below are pivotal to our nation’s ability to end both these potentially deadly infectious diseases.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest